KPTI - Karyopharm Therapeutics

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Cantor sees strong year ahead for oncology M&A
• Karyopharm Therapeutics GAAP EPS of -$0.36 misses by $0.07, revenue of $33.7M beats by $0.08M
• Karyopharm Therapeutics Q4 2023 Earnings Preview
• MorphoSys jumps amid report Novartis in takeover talks; Karyopharm surges in sympathy (update)
• Karyopharm expects FY total revenue to be ~$145.9 million
• Karyopharm reports encouraging data for endometrial cancer drug candidate
• Karyopharm Therapeutics GAAP EPS of -$0.30 misses by $0.05, revenue of $36M misses by $1.4M
• Karyopharm Therapeutics Q3 2023 Earnings Preview
• Karyopharm, Bristol Myers to evaluate drug combination for treatment of multiple myeloma
• Karyopharm Therapeutics GAAP EPS of -$0.29 beats by $0.06, revenue of $37.6M beats by $1.93M
• Karyopharm Therapeutics Q2 2023 Earnings Preview
• Biggest stock movers today: Charles Schwab, Transocean, Sunrun, Masimo and more
• Karyopharm granted Fast Track designation for selinexor for myelofibrosis
• Karyopharm hits four-month low after guidance cut
• Karyopharm Therapeutics GAAP EPS of -$0.30 beats by $0.08, revenue of $38.7M beats by $1.49M
• Cara, Iovance, and Karyopharm among biotechs with no exposure to SVB (updated)
• Karyopharm Therapeutics reports Q4 earnings miss; initiates FY23 outlook
• Karyopharm Therapeutics Q4 2022 Earnings Preview
• Karyopharm gains as Piper issues bullish remarks citing cancer drug
• Karyopharm Therapeutics announces $165M private placement